Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?
Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer? Int J Gynecol Cancer. 2013 Jun; 23(5):833-8.
View in:
PubMed
subject areas
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Bevacizumab
Carboplatin
Carboplatin
Cisplatin
Cisplatin
Cyclophosphamide
Cyclophosphamide
Disease Progression
Disease Progression
Drug Resistance, Neoplasm
Drug Resistance, Neoplasm
Female
Female
Follow-Up Studies
Follow-Up Studies
Humans
Humans
Middle Aged
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Recurrence, Local
Neoplasm Staging
Neoplasm Staging
Ovarian Neoplasms
Ovarian Neoplasms
Paclitaxel
Paclitaxel
Prognosis
Prognosis
Retrospective Studies
Retrospective Studies
Survival Rate
Survival Rate
Taxoids
Taxoids
Topotecan
Topotecan
authors with profiles
Debra L Richardson